Progress of venetoclax in treatment of hematologic malignancies / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 253-256, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-988979
ABSTRACT
The anti-apoptotic protein bcl-2, a key regulator of the intrinsic apoptotic pathway, is frequently overexpressed in cells of hematologic malignancies, and the small molecule inhibitor venetoclax that targets this apoptotic pathway has shown promising efficacy in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. The survival and prognosis of patients with acute myeloid leukemia who are of advanced age or who are unsuitable for strong induction chemotherapy because of comorbidities also have significantly improved, but some patients develop progressive drug resistance during the course of venetoclax treatment, which affects the efficacy of medical therapy. This article reviews the action mechanism, therapeutic progress and resistance mechanism of venetoclax in hematologic malignancies.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS